Genmab — Juni 2019
-
JNJ-372 looks very promissing according this. But the other day there were statements that efficiacy was not overwhelming! What should believe in?
-
OK thanks Sukkeralf and peter12. I will stop worrying
-
Der er i morgen jkj https://twitter.com/janssenus/status/1134882324125032450?s=21
-
Prof Maria-Victoria Mateos talks to ecancer at
2019 ASCO about the COLOMBA study into subcutaneous versus intravenous dara https://ecancer.org/video/7904/subcutaneous-versus-intravenous-daratumumab-administration-in-patients-with-relapsed-or-refractory-multiple-myeloma.php -
Myeloma. Skyrocketing drug prices https://twitter.com/rfonsi1/status/1134987324377501697?s=21
-
@Tandfeen-2 Cassiopeia would indeed be the 1st frontline transplant eligable combi, admittedly mostly a european regimen though i think. Next will be Griffin , Dara + VRd, we should get 1st data soon, but i think that is a year behind Cassiopeia
-
-
Revlimid (as I read it) . Also Dr Carlson from ICER says : However, using a cost-effectiveness threshold of $150,000 per quality-adjusted life-year, ICER found that “only the addition of daratumumab or panobinostat may be considered cost-effective options.”
-
Trump har igen i nat været på Twitter... "When you are the “Piggy Bank” Nation that foreign countries have been robbing and deceiving for years, the word TARIFF is a beautiful word indeed! Others must treat the United States fairly and with respect - We are no longer the “fools” of the past!"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind